Table 3 NY-ESO-1 expression in each tumour type
From: MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours
Type | Positive | Negative | Not Evaluable | Total | Positive Rate (%) |
|---|---|---|---|---|---|
Head and Neck | 10 | 55 | 1 | 66 | 15.4 |
Oesophageal | 55 | 162 | 4 | 221 | 25.3 |
Gastric | 0 | 5 | 0 | 5 | 0.0 |
Colorectal | 3 | 9 | 0 | 12 | 25.0 |
Lung | 6 | 15 | 0 | 21 | 28.6 |
Ovarian | 7 | 24 | 0 | 31 | 22.6 |
Endometrial | 3 | 5 | 0 | 8 | 37.5 |
Cervical | 0 | 3 | 1 | 4 | 0.0 |
Renal | 3 | 42 | 0 | 45 | 6.7 |
Prostate | 2 | 15 | 0 | 17 | 11.8 |